PARIS (Reuters) – Sanofi is poised to appoint Paul Hudson, a top executive with Switzerland’s Novartis, to become the French drugmaker’s next CEO from Sept. 1, a source familiar with the decision told Reuters on Thursday.
Current Sanofi SA CEO Olivier Brandicourt will leave the company to retire, said the source, who asked not to be named because of the sensitivity of the matter.
Hudson - Reputation
“Hudson has been chosen because of his reputation. He...